Chiara Lambertini
Impact in
- Oncology top 5%
- HER2/EGFR in Cancer Research
- Cancer Immunotherapy and Biomarkers
- CAR-T cell therapy research
- Cancer Treatment and Pharmacology
-
- Breast Cancer Treatment Studies
Papers in
- Oncology 19
- HER2/EGFR in Cancer Research 14
- Cancer Immunotherapy and Biomarkers 5
- Cancer Treatment and Pharmacology 3
- CAR-T cell therapy research 3
-
- Breast Cancer Treatment Studies 9
- Co-authors
- G. Paolo Dotto (2 shared papers)Reinhard Dummer (2 shared papers)Sanne Lysbet de Haas (3 shared papers)Sherene Loi (4 shared papers)Francisco J. Esteva (1 shared paper)Mark Beresford (1 shared paper)Seock‐Ah Im (1 shared paper)Jigna Shah (1 shared paper)
- Journals
- Annals of Oncology (5 papers)Clinical Cancer Research (2 papers)Journal of Clinical Oncology (2 papers)Blood (2 papers)Molecular Cancer Therapeutics (1 paper)
- Partner nations
- SwitzerlandUnited StatesGermany
In The Last Decade
Chiara Lambertini
22 papers receiving 858 citations
Hit Papers
Peers
Comparison fields: 5 of 68
- Oncology 607
- Cancer Research 148
- Radiology, Nuclear Medicine and Imaging 202
- Immunology 118
- Genetics 57
Countries citing papers authored by Chiara Lambertini
This map shows the geographic impact of Chiara Lambertini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chiara Lambertini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chiara Lambertini more than expected).
Fields of papers citing papers by Chiara Lambertini
This network shows the impact of papers produced by Chiara Lambertini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chiara Lambertini. The network helps show where Chiara Lambertini may publish in the future.
Co-authors
The 25 scholars most cited alongside Chiara Lambertini, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial Hit paper breakdown → | 2020 | 280 |
| 2 | 2008 | 159 | |
| 3 | 2022 | 82 | |
| 4 | 2005 | 53 | |
| 5 | 2012 | 42 | |
| 6 | 2010 | 36 | |
| 7 | 2023 | 28 | |
| 8 | 2011 | 27 | |
| 9 | 2023 | 23 | |
| 10 | 2021 | 23 | |
| 11 | 2022 | 22 | |
| 12 | 2020 | 21 | |
| 13 | 2013 | 20 | |
| 14 | 2022 | 15 | |
| 15 | 2022 | 15 | |
| 16 | 2021 | 3 | |
| 17 | 2013 | 3 | |
| 18 | 2015 | 3 | |
| 19 | 2021 | 3 | |
| 20 | 2024 | 2 |
About Chiara Lambertini
Chiara Lambertini is a scholar working on Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging, Molecular Biology and Pulmonary and Respiratory Medicine, having authored 26 papers that have together received 862 indexed citations. Recurring topics across this work include HER2/EGFR in Cancer Research (14 papers), Breast Cancer Treatment Studies (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Cancer Immunotherapy and Biomarkers (5 papers), Cancer Treatment and Pharmacology (3 papers), CAR-T cell therapy research (3 papers), Cancer-related gene regulation (2 papers) and Neuroendocrine Tumor Research Advances (2 papers). The work is most often cited by research in Oncology (607 citations), Cancer Research (148 citations), Radiology, Nuclear Medicine and Imaging (202 citations), Immunology (118 citations) and Genetics (57 citations). Chiara Lambertini has collaborated with scholars based in Switzerland, United States and Germany. Frequent co-authors include G. Paolo Dotto, Reinhard Dummer, Sanne Lysbet de Haas, Sherene Loi, Francisco J. Esteva, Mark Beresford, Seock‐Ah Im, Jigna Shah, Leisha A. Emens and Michelino De Laurentiis. Their work appears in journals such as Annals of Oncology, Clinical Cancer Research, Journal of Clinical Oncology, Blood and Molecular Cancer Therapeutics.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.